

Supporting Information for

Biocatalytic and chemical derivatization of fungal meroditerpenoid chevalone E

Zong-Hua Xiao,^{‡a} Jia-Yu Dong,^{‡a} Ao Li,^{‡b} Yan-Ping Li,^c Qiu-Fen Hu,^a Li-Dong Shao,^{*c} Yudai Matsuda,^{*d} and
Wei-Guang Wang^{*a}

^a Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission and Ministry of Education and Key Laboratory of Natural Products Synthetic Biology of Ethnic Medicinal Endophytes, State Ethnic Affairs Commission, Yunnan Minzu University, Kunming 650031, China.

^b Clinical Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China

^c Yunnan Key Laboratory of Southern Medicinal Utilization, School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, China.

^d Department of Chemistry, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR, China.

Table of Contents

Supplementary Methods	S2-S3
Supplementary Tables S1-S12	S4-S15
Supplementary Figures S1-S48	S16-S63
Supplementary References	S64

Supplementary Methods

Isolation and Purification of Each Metabolite

Purification conditions for chevalone F (**9**):

The extract from *A. oryzae* NSAR1 with *cle1*, *cle3*, *cle5*, *cle6*, *cle7*, and *olcF'* was subjected to silica-gel column chromatography and eluted stepwise using a dichloromethane: acetone gradient (100:0 to 50:50). Fractions that contained **9** were further purified by reverse-phase preparative HPLC (70% aqueous acetonitrile, 3.0 mL/min, $t_R = 20$ min), to yield 7.0 mg of a white solid: $[\alpha]_D^{20} -89.3$ (c 0.1, CHCl_3); for UV spectrum see Figure S1; for ^1H and ^{13}C NMR data see Table S5 and Figures S3 and S4; HRMS found m/z 413.2675 $[\text{M} + \text{H}]^+$ (calcd 413.2686 for $\text{C}_{26}\text{H}_{37}\text{O}_4$). The NMR data were in good agreement with the reported data.¹

Purification conditions for chevalone N (**10**):

The extract from *A. oryzae* NSAR1 with *cle1*, *cle2*, *cle3*, *cle5*, *cle6*, *cle7*, and *olcF'* was subjected to silica-gel column dichloromethane and eluted stepwise using a dichloromethane: acetone gradient (100:0 to 50:50). Fractions that contained **10** were further purified by reverse-phase preparative HPLC (65% aqueous acetonitrile, 3.0 mL/min, $t_R = 8.6$ min), to yield 3.6 mg of a white solid: $[\alpha]_D^{20} -87.3$ (c 0.1, CH_3OH); for UV spectrum see Figure S1; for ^1H and ^{13}C NMR data see Table S6 and Figures S5-S10; HRMS found m/z 429.2618 $[\text{M} + \text{H}]^+$ (calcd 429.2636 for $\text{C}_{26}\text{H}_{37}\text{O}_5$).

Purification conditions for chevalone O (**11**):

The extract from *A. oryzae* NSAR1 with *cle1*, *cle3*, *cle4*, *cle5*, *cle6*, *cle7*, and *olcF'* was purified by reverse-phase preparative HPLC with a solvent system of water (solvent A) and acetonitrile (solvent B) at a flow rate of 3.0 mL/min. Separation was performed with solvent B/solvent A using a linear gradient from 10:90 to 100:0 for 30 min ($t_R = 23.5$ min), which yielded 5.1 mg of a white solid: $[\alpha]_D^{20} -78.7$ (c 0.1, CH_3OH); for UV spectrum see Figure S1; for ^1H and ^{13}C NMR data see Table S7 and Figures S11-S16; HRMS found m/z 429.2647 $[\text{M} + \text{H}]^+$ (calcd 429.2636 for $\text{C}_{26}\text{H}_{37}\text{O}_5$).

Purification conditions for chevalone P (**12**):

The extract from *A. oryzae* NSAR1 with *cle1*, *cle3*, *cle4*, *cle5*, *cle6*, *cle7*, and *olcF'* was purified by reverse-phase preparative HPLC with a solvent system of water (solvent A) and acetonitrile (solvent B) at a flow rate of 3.0 mL/min. Separation was performed with solvent B/solvent A using a linear gradient from 10:90 to 100:0 for 30 min ($t_R = 15.1$ min), which yielded 14.1 mg of a white solid: $[\alpha]_D^{20} -106.3$ (c 0.2, CH_3OH); for UV spectrum see Figure S1; for ^1H and ^{13}C NMR data see Table S8 and Figures S17-S22; HRMS found m/z 445.2605 $[\text{M} + \text{H}]^+$ (calcd 445.2585 for $\text{C}_{26}\text{H}_{37}\text{O}_6$).

Purification conditions for chevalone Q (**13**):

The extract from *A. oryzae* NSAR1 with *cle1*, *cle2*, *cle3*, *cle4*, *cle5*, *cle6*, *cle7*, and *olcF'* was subjected to silica-gel column dichloromethane and eluted stepwise using a dichloromethane: acetone gradient (100:0 to 50:50). Fractions that contained **13** were further purified by reverse-phase preparative HPLC (40% aqueous acetonitrile, 3.0 mL/min, t_R = 13.2 min), to yield 8.0 mg of a white solid: $[\alpha]_D^{20}$ -14.0 (c 0.05, CH₃OH); for UV spectrum see Figure S1; for ¹H and ¹³C NMR data see Table S9 and Figures S23-S28; HRMS found m/z 445.2583 [M + H]⁺ (calcd 445.2585 for C₂₆H₃₇O₆).

Purification conditions for chevalone R (**14**):

The extract from *A. oryzae* NSAR1 with *cle1*, *cle2*, *cle3*, *cle4*, *cle5*, *cle6*, *cle7*, and *olcF'* was subjected to silica-gel column dichloromethane and eluted stepwise using a dichloromethane: acetone gradient (100:0 to 50:50). Fractions that contained **14** were further purified by reverse-phase preparative HPLC (30% aqueous acetonitrile, 3.0 mL/min, t_R = 16.0 min), to yield 1.6 mg of a white solid: $[\alpha]_D^{20}$ -26.7 (c 0.05, CH₃OH); for UV spectrum see Figure S1; for ¹H and ¹³C NMR data see Table S10 and Figures S29-S34; HRMS found m/z 461.2515 [M + H]⁺ (calcd 461.2534 for C₂₆H₃₇O₇).


Purification conditions for chevalone S (**15**):

The *A. oryzae* NSAR1 transformant harboring *cle1+2+3+5+6+7* was cultivated in 200 ml of DPY medium at 30 °C and 200 rpm for 72 h, in the presence of 5 mg of **11**. After the incubation, the extract was subjected to silica-gel column dichloromethane and eluted stepwise using a dichloromethane: acetone gradient (100:0 to 50:50). Fractions that contained **15** were further purified by reverse-phase preparative HPLC (60% aqueous acetonitrile, 3.0 mL/min, t_R = 7.2 min), to yield 1.5 mg of a white solid; for UV spectrum see Figure S1; HRMS found m/z 441.2275 [M + H]⁺ (calcd 441.2277 for C₂₆H₃₃O₆); ¹H NMR (400 MHz, pyridine-*d*₅) δ_H 6.23 (brs, 1H), 5.01 (dd, J = 7.6, 3.5 Hz, 1H), 2.82 – 2.61 (m, 3H), 2.46 – 2.28 (m, 3H), 2.06 (s, 3H), 1.59 (s, 3H), 1.39 (s, 3H), 1.19 (s, 3H), 1.00 (s, 3H); ¹³C NMR (100 MHz, pyridine-*d*₅) δ_C 213.6 s, 180.2 s, 177.6 s, 163.3 s, 161.2 s, 112.9 d, 100.2 s, 83.3 s, 75.2 d, 56.9 d, 49.3 d, 48.6 d, 48.1 s, 47.5 s, 39.5 t, 34.7 t, 34.4 t, 34.0 s, 33.5 t, 27.3 q, 25.3 q, 21.7 q, 20.2 t, 19.3 q, 16.6 q, 16.5 t; for NMR data see Figures S35 and S36.

Purification conditions for chevalone T (**16**):


The extract from *A. oryzae* NSAR1 with *cle1*, *cle2*, *cle3*, *cle4*, *cle5*, *cle6*, *cle7*, and *olcF'* was subjected to silica-gel column dichloromethane and eluted stepwise using a dichloromethane: acetone gradient (100:0 to 50:50). Fractions that contained **16** were further purified by reverse-phase preparative HPLC (45% aqueous acetonitrile, 3.0 mL/min, t_R = 6.0 min), to yield 2.3 mg of a white solid: $[\alpha]_D^{20}$ -72.0 (c 0.05, CH₃OH); for UV spectrum see Figure S1; for ¹H and ¹³C NMR data see Table S11 and Figures S37-S42; HRMS found m/z 457.2227 [M + H]⁺ (calcd 457.2221 for C₂₆H₃₃O₇).

Chemical synthesis of **17** from **10**:



According to the literature,² to a suspension of **10** (10 mg, 0.02 mmol), (diacetoxyiodo)benzene (PIDA) (12 mg, 0.03 mmol), and I₂ (6 mg, 0.02 mmol) in cyclohexane (5 mL) was irradiated with a tungsten-filament lamp (250 W) at 40 °C under an argon atmosphere for 8 h. The reaction was diluted with dichloromethane (15 mL) and quenched by saturated aqueous solution of Na₂S₂O₃ (0.8 mL). The organic layer was washed with brine (10 mL × 3), dried over Na₂SO₄, and concentrated. The residue was purified by preparative HPLC (65% aqueous acetonitrile, 3.0 mL/min, *t*_R = 10.5 min), to give 4.2 mg of **17** (42% yields, 66% brsm.) with a white solid: [α]¹⁸_D -132.3 (*c* 0.1, CHCl₃); for UV spectrum see Figure S1; for ¹H and ¹³C NMR data see Table S12 and Figures S43-S48; HRMS found *m/z* 427.2464 [M + H]⁺ (calcd 427.2479 for C₂₆H₃₅O₅).

Table S1. Annotation of each protein encoded by the *olc'* cluster.



Gene	Amino acids (base pairs)	Protein homologue, origin	Similarity/identity (%)	Proposed function
<i>olcA'</i>	2442 (7329)	OlcA, <i>Penicillium canescens</i>	57/42	polyketide synthase
<i>olcB'</i>	1534 (493)	OlcB, <i>Penicillium canescens</i>	75/57	cytochrome P450 monooxygenase
<i>olcC'</i>	1167 (335)	OlcC, <i>Penicillium canescens</i>	82/67	geranylgeranyl pyrophosphate synthase
<i>olcD'</i>	768 (236)	OlcD, <i>Penicillium canescens</i>	69/55	terpene cyclase
<i>olcE'</i>	1626 (501)	OlcE, <i>Penicillium canescens</i>	64/51	FAD-dependent monooxygenase
<i>olcF'</i>	948 (257)	OlcF, <i>Penicillium canescens</i>	79/65	short-chain dehydrogenase/reductase
<i>olcG'</i>	1781 (521)	OlcG, <i>Penicillium canescens</i>	71/55	cytochrome P450 monooxygenase
<i>olcH'</i>	1069 (321)	OlcH, <i>Penicillium canescens</i>	79/63	prenyltransferase
<i>olcI'</i>	1812 (572)	OlcI, <i>Penicillium canescens</i>	68/54	CoA ligase
<i>olcJ'</i>	1652 (511)	OlcJ, <i>Penicillium canescens</i>	79/63	cytochrome P450 monooxygenase
<i>olcK'</i>	876 (291)	OlcK, <i>Penicillium canescens</i>	75/59	Fe(II)/ α KG-dependent dioxygenase
<i>olcM'</i>	504 (167)	LnaC, <i>Aspergillus flavus</i>	47/23	truncated cytochrome P450 monooxygenase

Table S2. Primers used in this study.

Primer	Sequence (5' to 3')
InF-adeA-SpeI-F	TTACCTAGAGGATCTACTAGCGACTCCAATCTTCAAGAGC
InF-adeA-SpeI-R	TCCCCAATCCATATGACTAGGTAAGATACATGAGCTTCGGTG
olcF'-F	CCCACAGCAAGCTCCGAATTATGGGCTGTCTCCAGAATCGCG
olcF'-R	CCGGGTACCGAGCTCGAATTTTATATAGTAGACCAGCCATCGT
olcB'-F	CCCACAGCAAGCTCCGAATTATGATGGCCCTTGTGCTCTG
olcB'-R	CCGGGTACCGAGCTCGAATTTCTAATTACCTTTGCCCTTCCC
InF-PamyB-F	TGCCTGCAGGTCGACTCTAGACGACTCCAATCTTCAAGAGC
InF-TamyB-R	ATGACTAGTAGATCCTCTAGGTAAGATACATGAGCTTCGGTG
InF-linker-F1	TTGCTCGCGAGCGCGTTCCACTGCATCATCAGTCTAGA
InF-linker-R1	TGGAACGCGCTCGCGAGCAAGTACCATACAGTACCGCG
InF-pBARI-F	TGATTACGCCAAGCTTCGACTCCAATCTTCAAGAGC
InF-pBARI-R	GCAGGCATGCAAGCTTGTAAGATACATGAGCTTCG
pET28a-olcF'-NcoI-F	AGAAGGAGATATACCATGGGCTGTCTCCAGAATCGC
pET28a-olcF'-XhoI-R	GGTGGTGGTGCTCGTATATAGTAGACCAGCCATCGT

Table S3. Plasmids constructed in this study and PCR conditions for the amplification of the inserts for the plasmid constructions.

Plasmid	Vector	Insert	Primer 1	Primer 2	PCR Template
pTAex3-olcF'	pTAex3 digested with <i>EcoRI</i>	<i>olcF'</i>	olcF'-F	olcF'-R	<i>A. felis</i> gDNA
pTAex3-olcB'	pTAex3 digested with <i>EcoRI</i>	<i>olcB'</i>	olcB'-F	olcB'-R	<i>A. felis</i> gDNA
pET28a-olcF'	pET28a digested with <i>NcoI</i> and <i>XhoI</i>	<i>olcF'</i>	pET28a-olcF'-NcoI-F	pET28a-olcF'-XhoI-R	<i>A. felis</i> cDNA
pAdeA-cle1+5+6	pAdeA-cle5+6 digested with <i>SpeI</i>	<i>PamyB-cle1-TamyB</i>	InF-adeA-SpeI-F	InF-adeA-SpeI-R	pTAex3-cle1
pBARI-cle2+olcF'	pBARI digested with <i>HindIII</i>	<i>PamyB-cle2-TamyB</i>	InF-pBARI-F	InF-linker-R1	pTAex3-cle2
		<i>PamyB-olcF'-TamyB</i>	InF-linker-F1	InF-pBARI-R	pTAex3-olcF'
pBARI-cle4+olcF'	pBARI digested with <i>HindIII</i>	<i>PamyB-cle4-TamyB</i>	InF-pBARI-F	InF-linker-R1	pTAex3-cle4
		<i>PamyB-olcF'-TamyB</i>	InF-linker-F1	InF-pBARI-R	pTAex3-olcF'

Table S4. *Aspergillus oryzae* NSAR1 transformants constructed in this study.

Strain	Plasmids used for transformation
<i>A. oryzae</i> / <i>cle1+3+5+6+7</i>	pAdeA- <i>cle1+5+6</i> ; pUSA- <i>cle3+7</i>
<i>A. oryzae</i> / <i>cle1+3+5+6+7+olcF'</i>	pAdeA- <i>cle1+5+6</i> ; pUSA- <i>cle3+7</i> ; pTAex3- <i>olcF'</i>
<i>A. oryzae</i> / <i>cle1+2+3+5+6+7+olcF'</i>	pAdeA- <i>cle1+5+6</i> ; pUSA- <i>cle3+7</i> ; pBARI- <i>cle2+olcF'</i>
<i>A. oryzae</i> / <i>cle1+3+4+5+6+7+olcF'</i>	pAdeA- <i>cle1+5+6</i> ; pUSA- <i>cle3+7</i> ; pBARI- <i>cle4+olcF'</i>
<i>A. oryzae</i> / <i>cle1+2+3+4+5+6+7+olcF'</i>	pAdeA- <i>cle1+5+6</i> ; pUSA- <i>cle3+7</i> ; pBARI- <i>cle2+olcF'</i> ; pTAex3- <i>cle4</i>
<i>A. oryzae</i> / <i>cle1+2+3+5+6+7+olcB'+F'</i>	pAdeA- <i>cle1+5+6</i> ; pUSA- <i>cle3+7</i> ; pBARI- <i>cle2+olcF'</i> ; pTAex3- <i>olcB'</i>




Table S5. NMR data for chevalone F (**9**) (^1H NMR:400 MHz, ^{13}C NMR: 100 MHz, δ in ppm, recorded in CDCl_3).

position	^{13}C	^1H		
	δ (ppm)	δ (ppm)	Multiplicity	intensity
1	39.2 t	1.48	overlap	1H
2	34.0 t	1.97	overlap	1H
		2.50	m	2H
3	217.5 s			
4	47.4 s			
5	54.8 d	1.43 α	overlap	1H
6	19.2 t	1.39	overlap	1H
		1.57	overlap	1H
7	40.3 t	1.08	overlap	1H
		1.95	overlap	1H
8	37.4 s			
9	59.7 d	0.95	overlap	1H
10	36.9 s			
11	19.3 t	1.42	overlap	1H
		1.73	overlap	1H
12	40.2 t	1.71	overlap	1H
		2.12	d ($J = 6.3$ Hz)	1H
13	84.2 s			
14	52.3 d	1.51 α	overlap	1H
15	15.5 t	2.15	dd ($J = 7.0, 3.4$ Hz)	1H
		2.55	m	1H
16	20.7 q	1.30 β	d ($J = 0.8$ Hz)	3H
17	15.8 q	0.92 β	s	3H
18	16.3 q	0.93 β	s	3H
19	26.8 q	1.01 α	d ($J = 2.2$ Hz)	3H
20	21.0 q	1.04 β	s	3H
1'	180.7 s			
2'	98.5 s			
3'	162.7 s			
4'	112.0 d	5.99	d ($J = 1.0$ Hz)	1H
5'	160.7 s			
6'	19.4 q	2.20	d ($J = 0.9$ Hz Hz)	3H




Table S6. NMR data for chevalone N (**10**) (^1H NMR: 600 MHz, ^{13}C NMR: 150 MHz, δ in ppm, recorded in pyridine- d_5).

position	^{13}C		^1H				
	δ (ppm)	δ (ppm)	Multiplicity	intensity	HMBC correlation	COSY correlation	NOESY correlation
1	35.7 t	1.09 α	dd ($J = 10.3, 7.6$ Hz)	1H	2, 3, 5, 9, 10, 20	H-1 β , H-2 α	H-1 β , H-2 α , H-9 α
		2.22 β	dt ($J = 12.5, 4.2$ Hz)	1H	2, 3, 5, 10, 20	H-1 α , H-2 α , H-2 β	H-1 α , H-11 β , H-20 α , H-20 β
2	30.9 t	2.11 α	dd ($J = 12.5, 3.3$ Hz)	1H	1, 3, 4, 10	H-1 α , H-1 β	H-2 β
		2.37 β	td ($J = 12.5, 5.5$ Hz)	1H	1, 3, 4, 10	H-1 α , H-1 β	H-2 α , H-19 α
3	98.5 s						
4	41.3 s						
5	49.9 d	1.27 α	dd ($J = 8.9, 5.4$ Hz)	1H	1, 3, 4, 6, 7, 9, 10, 18, 19, 20	H-6 α , H-6 β	H-6 α , H-7 α , H-9 α , H $_3$ -19 α
		1.12 α	overlap	1H	4, 5, 7, 8, 10	H-5 α , H-6 β , H-7 α , H-7 β	H-5 α , H-6 β , H-7 β
6	20.1 t	1.03 β	overlap	1H	4, 5, 7, 10	H-5 α , H-6 α , H-7 α , H-7 β	H-6 α , H-7 α , H $_3$ -15 β
		1.69 α	overlap	1H	6, 9, 14	H-6 α , H-6 β , H-7 β	H-6 α , H-7 α
7	38.6 t	0.92 β	dd ($J = 5.5, 3.5$ Hz)	1H	5, 6, 8, 9, 15	H-6 α , H-6 β , H-7 α	H-6 α , H-7 β , H $_3$ -15 β
8	36.9 s						
9	54.8 d	1.01 α	overlap	1H	1, 5, 8, 10, 11, 12, 14, 15, 20	H-11 β	H-1 α , H-5 α , H-7 α , H-11 α , H-12 α , H-14 α
10	36.1 s						
11	19.9 t	1.70 α	overlap	1H	8, 9, 10, 12, 13	H-11 β , H-12 β	H-9 α , H-11 β , H-12 α
		1.48 β	m	1H	8, 9, 12, 13	H-9 α , H-11 α , H-12 α , H-12 β	H-11 α , H $_3$ -15 β
12	40.9 t	2.02 α	d ($J = 3.8$ Hz)	1H	9, 11, 13, 14, 16	H-11 β , H-12 β	H-9 α , H-11 α , H-14 α
		1.67 β	overlap	1H	9, 11, 13, 14, 16	H-11 α , H-11 β , H-12 α	H-11 β , H $_3$ -16 β
13	84.2 s						
14	52.2 d	1.45 α	dd ($J = 12.7, 4.9$ Hz)	1H	7, 8, 9, 12, 13, 15, 16, 17, 2'	H-17 α , H-17 β	H-9 α , H-12 α , H-17 α
15	14.9 q	0.69 β	s	3H	7, 8, 9, 14		H-7 β , H $_3$ -16 β , H-17 β , H-20 α , H-20 β
		1.18 β	s	3H	12, 13, 14		H-11 β , H-12 β , H $_3$ -15 β , H-17 β
17	16.6 t	2.79 α	dd ($J = 16.3, 4.9$ Hz)	1H	8, 13, 14, 1', 2', 3'	H-14 α , H-17 β	H-14 α , H-17 β
		2.27 β	dd ($J = 16.3, 12.7$ Hz)	1H	8, 13, 14, 1', 2', 3'	H-14 α , H-17 α	H $_3$ -15 β , H $_3$ -16 β , H-17 α
18	19.9 q	1.32 β	s	3H	3, 4, 5, 19		H-2 β , H-6 β , H $_3$ -19 α , H-20 α , H-20 β
		1.25 α	s	3H	3, 4, 5, 18		H-5 α , H-6 α , H $_3$ -18 β
20	67.9 t	4.26 α	dd ($J = 8.7, 2.8$ Hz)	1H	1, 3, 5, 9, 10		H-1 β , H-6 β , H-11 β , H $_3$ -15 β , H $_3$ -18 β
		3.83 β	dd ($J = 8.7, 2.0$ Hz)	1H	1, 3, 5, 9, 10		H-1 β , H-6 β , H-11 β , H $_3$ -15 β , H $_3$ -18 β
1'	163.1 s						
2'	99.1 s						
3'	180.3 s						
4'	112.7 d	6.20	s	1H	2', 3', 5', 6'		H $_3$ -6'
5'	161.1 s						
6'	19.3 q	2.04	s	3H	4', 5'		H-4'




Table S7. NMR data for chevalone O (**11**) (^1H NMR: 600 MHz, ^{13}C NMR: 150 MHz, δ in ppm, recorded in CDCl_3).

position	^{13}C		^1H				
	δ (ppm)	δ (ppm)	Multiplicity	intensity	HMBC correlation	COSY correlation	NOESY correlation
1	39.1 t	1.49 α 2.13 β	m m	1H 1H	2, 3, 5, 10, 20 2, 3, 5, 9, 10	H-1 β , H-2 α H-1 α , H-2 β	H-1 β , H-2 α , H-9 α H-1 α , H-2 β , H ₃ -20 β
2	34.1 t	2.44 α 2.66 β	ddd ($J = 15.9, 7.0, 3.6$ Hz) m	1H 1H	1, 3, 4, 10 1, 3, 4, 10	H-1 α H-1 β	H-1 β H-1 α , H-2 β
3	217.3 s						
4	47.5 s						
5	56.1 d	1.33 α	dd ($J = 12.4, 2.5$ Hz)	1H	1, 4, 7, 8, 9, 10, 18, 19, 20	H-6 β	H-6 α , H-9 α , H ₃ -19 α
6	19.6 t	1.71 α 1.57 β	m m	1H 1H	4, 5, 7, 8, 10 4, 5, 7, 10	H-6 β H-5 α , H-6 α , H-7 α	H-5 α , H-6 β , H-7 β H-6 α
7	42.6 t	1.94 α 1.05 β	dd ($J = 5.4, 3.0$ Hz) overlap	1H 1H	5, 6, 8, 14, 15 5, 6, 8, 9, 15	H-6 β , H-7 β H-6 α , H-7 α	H-5 α , H-6 α , H-6 β , H-7 β H-6 α , H-6 β , H-7 α , H ₃ -15 β
8	37.7 s						
9	60.3 d	0.99 α	s	1H	1, 5, 8, 10, 11, 12, 14, 15, 20	H-11 α	H-1 α , H-5 α , H-14 α
10	37.9 s						
11	67.6 d	4.66 α	s	1H	8, 9, 12, 13	H-9 α , H-11 β	H-9 α , H-12 α , H-12 β
12	48.5 t	2.26 α 1.91 β	dd ($J = 8.3, 5.6$ Hz) overlap	1H 1H	9, 13, 16 9, 13, 14, 16	H-12 β H-11 β	H-9 α , H-11 α , H-14 α H-12 α , H ₃ -16 β
13	84.1 s						
14	53.0 d	1.53 α	m	1H	7, 8, 9, 12, 15, 16, 17, 2'	H-17 α , H-17 β	H-9 α , H-12 α , H-17 α
15	17.1 q	1.30 β	s	3H	7, 8, 9, 14		H ₃ -16 β , H-17 β , H ₃ -20 β
16	22.0 q	1.54 β	s	3H	12, 13, 14		H-12 β , H ₃ -15 β , H-17 β
17	15.5 t	2.61 β 2.29 α	dd ($J = 16.2, 4.6$ Hz) overlap	1H 1H	8, 13, 14, 1', 2', 3' 8, 13, 14, 1', 2'	H-14 α , H-17 α H-14 α , H-17 β	H-7 α , H-17 β H-7 β , H-14 α , H-17 α
18	21.3 q	1.08 β	s	3H	3, 4, 5, 19		H-2 β , H-6 β , H ₃ -19 α
19	26.6 q	1.07 α	s	3H	3, 4, 5, 18		H-3 α , H-5 α , H ₃ -18 β
20	17.3 q	1.37 β	s	3H	1, 5, 9, 10		
1'	162.4 s						
2'	98.8 s						
3'	180.7 s						
4'	112.1 d	5.99	s	1H	2', 3', 5', 6'		H ₃ -6'
5'	160.7 s						
6'	19.4 q	2.21	s	3H	4', 5'		





Table S8. NMR data for chevalone P (**12**) (^1H NMR: 600 MHz, ^{13}C NMR: 150 MHz, δ in ppm, recorded in pyridine- d_5).


position	^{13}C		^1H				
	δ (ppm)	δ (ppm)	Multiplicity	intensity	HMBC correlation	COSY correlation	NOESY correlation
1	39.3 t	1.36 α 2.07 β	m m	1H 1H	2, 3, 5, 10, 20 2, 3, 5, 9, 10, 20	H-1 β , H-2 α H-1 α , H-1 β , H-2 β	H-1 β , H-2 α , H-9 α H-1 α , H-2 α , H ₃ -20 β
2	34.7 t	2.40 α 2.65 β	ddd ($J = 15.5, 7.0, 3.6$ Hz) ddd ($J = 15.5, 10.6, 7.5$ Hz)	1H 1H	1, 3, 4, 10 1, 3, 10	H-1 α , H-2 β H-1 α , H-1 β , H-2 α ,	H-1 α , H-1 β , H-2 β H-1 β , H-2 α , H ₃ -18 β
3	216.5 s						
4	47.8 s						
5	56.3 d	1.31 α	dd ($J = 12.4, 2.4$ Hz),	1H	1, 4, 6, 7, 9, 10, 18, 19, 20	H ₂ -6	H-6 α , H-6 β , H-9 α , H ₃ -19 α
6	20.1 t	1.61 α 1.42 β	dd ($J = 12.4, 5.0$ Hz) overlap	1H 1H			H-5 α , H-6 β , H-7 α H-5 α , H-7 β
7	42.9 t	1.71 β 0.96 α	dt ($J = 12.6, 3.3$ Hz) td ($J = 12.6, 3.7$ Hz)	1H 1H	5, 8 5, 8, 9, 14 5, 6, 8, 14, 15	H-5 α , H-7 α H ₂ -6, H-7 α H ₂ -6, H-7 β	H-6 α , H-6 β , H-7 α , H ₃ -15 β H-6 α , H-6 β , H-7 β
8	38.3 s						
9	59.4 d	1.02 α	s	1H	1, 5, 7, 8, 10, 11, 12, 14, 15, 20	H ₂ -11	H-1 α , H-7 α , H ₂ -11, H-14 α
10	38.4 s						
11	71.8 d	4.73 α	d ($J = 1.2$ Hz)	1H	8, 9, 12, 13	H-9 α , H-12 α	H-1 α , H-9 α , H-12 α
12	78.4 d	4.06 α	d ($J = 3.4$ Hz)	1H	13, 14, 16	H-11 α	H-9 α , H-11 α , H-14 α ,
13	89.1 s						
14	51.9 d	1.64 α	dd ($J = 12.7, 4.8$ Hz)	1H	7, 8, 9, 12, 13, 16, 2'	H-17 α , H-17 β	H-9 α , H-12 α , H-17 α , H-17 β
15	17.5 q	1.44 β	s	3H	7, 8, 9, 14		H-7 β , H ₃ -16 β , H-17 β , H ₃ -20 β
16	16.4 q	1.80 β	s	3H	12, 13, 14		H ₃ -15 β , H-17 β
17	16.3 t	2.90 α 2.58 β	dd ($J = 16.2, 4.8$ Hz) dd ($J = 16.2, 12.7$ Hz)	1H 1H	13, 14, 1', 2', 3' 8, 13, 14, 1', 2'	H-14 α , H-17 β H-14 α , H-17 β	H-14 α , H-17 α H ₃ -15 β , H ₃ -16 β , H-17 α
18	21.7 q	1.09 β	s	3H	3, 4, 5, 19		H-2 β , H ₂ -6, H ₃ -19 α
19	27.0 q	1.15 α	s	3H	3, 4, 5, 18		H-2 α , H-5 α , H ₃ -18 β
20	18.0 t	1.59 β	s	3H	1, 5, 9, 10		H-1 β , H ₃ -15 β , H ₃ -18 β
1'	163.2 s						
2'	99.1 s						
3'	180.2 s						
4'	112.8 d	6.22	s	1H	2', 3', 5', 6'		H ₃ -6'
5'	161.1 s						
6'	19.3 q	2.04	s	3H	4', 5'		
11-OH		6.08		1H			
12-OH		5.02		1H			



13

Table S9. NMR data for chevalone Q (**13**) (^1H NMR: 500 MHz, ^{13}C NMR: 125 MHz, δ in ppm, recorded in pyridine- d_5).

position	^{13}C		^1H				
	δ (ppm)	δ (ppm)	Multiplicity	intensity	HMBC correlation	COSY correlation	NOESY correlation
1	35.6 t	1.22 α 2.48 β	d ($J = 7.4$ Hz) dd ($J = 7.4, 5.2$ Hz)	1H 1H	3, 5, 9, 20 2, 5, 10	H-1 β , H-2 α H-1 α , H-2 β	H-2 α , H-5 α H ₂ -20 β
2	31.1 t	2.13 α 2.41 β	m m	1H 1H	4, 10 1	H-1 α , H-1 β , H-2 α H-1 β , H-2 β	H-2 β H-1 β , H-2 α
3	98.0 s						
4	41.3 s						
5	51.2 d	1.29 α	d ($J = 4.1$ Hz)	1H	1, 3, 4, 7, 9, 10, 18, 19, 20	H-6 β	H-1 α , H-6 α , H-9 α , H ₃ -19 α
6	20.6 t	1.56 β 1.90 α	m overlap	1H 1H	5, 8, 10 4, 5, 8, 10	H-5 α H-7 α	H-5 α H-7 β
7	41.5 t	1.02 β 1.74 α	t ($J = 12.8$ Hz) d ($J = 6.7$ Hz)	1H 1H	8, 14, 15 5, 6, 8, 9, 14, 15	H-7 α , H-12 β H-6 β , H-7 β	H-7 α , H ₃ -15 β H-14 α , H-9 α
8	37.4 s						
9	57.0 d	1.17 α	s	1H	1, 5, 8, 10, 11, 12, 14, 15, 20	H-11 α	H-12 α , H-14 α
10	37.4 s						
11	66.1 d	4.8 α	br s	1H	13	H-9 α , H-12 α , H-12 β	H-9 α , H-12 α , H-12 β
12	48.5 t	2.02 β 2.45 α	s m	1H 1H	13, 14, 16 9, 11, 13, 14, 16	H-7 β , H-11 α H-11 α	H ₃ -16 β H-14 α
13	84.8 s						
14	52.8 d	1.64 α	dd ($J = 12.6, 4.8$ Hz)	1H	7, 8, 9, 12, 13, 15, 16	H-17 α	H-7 α , H-9 α , H-12 α , H-17 α
15	16.7 q	1.32 β	s	3H	7, 8, 9, 14		H ₃ -16 β , H-20b
16	22.6 q	1.68 β	s	3H	12, 13, 14		H ₃ -15 β
17	16.7 t	2.52 β 2.91 α	overlap dd ($J = 16.4, 4.8$ Hz)	1H 1H	8, 13, 14, 1', 2' 13, 14, 1', 2', 3'		H ₃ -15 β , H ₃ -16 β H-14 α
18	19.9 q	1.37 β	s	3H	3, 4, 5, 19	H-14 α , H-17 β	H-14 α
19	28.1 q	1.27 α	s	3H	3, 4, 5, 18		H-20 α
20	69.4 t	4.67 α 5.01 β	dd ($J = 9.4, 2.9$ Hz) dd ($J = 9.4, 1.8$ Hz)	1H 1H	1, 5, 10 1, 3, 5, 10	H-20 α H-20 β	H ₃ -17 β H-20 α
1'	163.0 s						
2'	99.4 s						
3'	180.3 s						
4'	112.7 d	6.22	s	1H	2', 5', 6'		H ₃ -6'
5'	161.1 s						
6'	19.3 q	2.05	s	3H	4', 5'		H-4'



14

Table S10. NMR data for chevalone R (**14**) (^1H NMR: 600 MHz, ^{13}C NMR: 150 MHz, δ in ppm, recorded in pyridine- d_5).

position	^{13}C		^1H				
	δ (ppm)	δ (ppm)	Multiplicity	intensity	HMBC correlation	COSY correlation	NOESY correlation
1	35.5 t	2.45 β 1.17 α	m m	1H 1H	2, 3, 5, 10, 20 3, 10, 20	H-1 α H-1 β , H-2 α	H-1 α , H ₂ -20 H-1 β , H-2 α
2	31.1 t	2.38 β 2.09 α	td ($J = 12.1, 5.4$ Hz) m	1H 1H	3, 10 1, 3, 10	H-1 β H-1 β	H-1 α H-1 α , H-1 β
3	98.1 s						
4	41.5 s						
5	51.1 d	1.31 α	dd ($J = 13.0, 4.4$ Hz)	1H	3, 4, 7, 10, 18, 19, 20	H ₂ -6	H-1 α , H-7 α , H-9 α
6	20.7 t	1.90 α 1.57 β	dd ($J = 13.0, 3.3$ Hz) dd ($J = 14.3, 4.4$ Hz)	2H	4, 5, 7, 8	H-5 α , H-7 α	H-5 α , H-6 β H-5 α , H-6 α , H-7 α , H ₃ -15 β
7	41.2 t	1.76 α 1.01 β	d ($J = 12.8$ Hz) td ($J = 12.0, 4.5$ Hz)	1H 1H	5, 8, 9, 14, 15 5, 8, 9, 14, 15	H ₂ -6, H-7 β H-7 α	H-5 α , H-6 α , H-7 β , H-14 α H-7 α , H ₃ -15 β , H-17 β
8	37.5 s						
9	55.8 d	1.24 α	s	1H	1, 5, 7, 8, 10, 11, 12, 14, 15, 20	H-11 α	H-5 α , H-11 α , H-12 α , H-14 α
10	37.3 s						
11	71.1 d	4.80 α	s	1H	8, 9, 12, 13	H-9 α , H-12 α	H-1 α , H-12 α
12	78.2 d	4.07 α	t ($J = 4.5$ Hz)	1H	13, 16	H-11 α	H-9 α , H-11 α , H-14 α
13	89.0 s						
14	51.5 d	1.63 α	dd ($J = 12.5, 4.8$ Hz)	1H	8, 9, 12, 13, 15, 16, 17, 2'	H-17 α , H-17 β	H-7 α , H-9 α , H-12 α , H-17 α
15	16.7 q	1.35 β	s	3H	7, 8, 9, 14		H ₃ -16 β , H-17 β , H ₂ -20
16	16.6 q	1.79 β	s	3H	12, 13, 14		H ₃ -15 β , H-17 β , H ₂ -20
17	16.5 t	2.95 α 2.55 β	dd ($J = 16.2, 4.8$ Hz) dd ($J = 16.2, 12.5$ Hz)	1H 1H	8, 13, 14, 1', 2' 13, 14, 1', 2', 3'	H-14 α , H-17 β H-14 α , H-17 α	H-7 α , H-14 α , H-17 β H ₃ -15 β , H ₃ -16 β , H-17 α
18	20.0 q	1.38 β	s	3H	3, 4, 5, 19		H-6 β
19	28.1 q	1.26 α	s	3H	3, 4, 5, 18		H-5 α
20	69.7 t	5.05 α 4.73 β	d ($J = 9.4$ Hz) dd ($J = 9.4, 2.8$ Hz)	1H 1H	1, 5, 9, 10 1, 5, 9, 10	H-20 β H-20 α	H-20 β H ₃ -18 β , H-20 α
1'	163.2 s						
2'	99.1 s						
3'	180.2 s						
4'	112.8 d	6.21	s	1H	2', 3', 5', 6'		H ₃ -6'
5'	161.0 s						
6'	19.3 q	2.04	s	3H	4', 5'		H-4'




Table S11. NMR data for chevalone T (**16**) (^1H NMR: 600 MHz, ^{13}C NMR: 150 MHz, δ in ppm, recorded in pyridine- d_5).

position	^{13}C		^1H				
	δ (ppm)	δ (ppm)	Multiplicity	intensity	HMBC correlation	COSY correlation	NOESY correlation
1	33.2 t	2.37 β	ddd ($J = 13.5, 7.6, 3.2$ Hz)	1H	2, 3, 5, 10, 20	H-1 α	H-1 β , H-2 β
		1.85 α	overlap	1H	2, 3, 9, 10, 20	H-1 β , H-2 α	H-1 α , H-2 α , H-9 α
		2.77 β	ddd ($J = 16.8, 10.7, 7.3$ Hz)	1H	1, 3, 4	H-1 α	H-1 β
2	34.3 t	2.62 α	ddd ($J = 16.8, 7.3, 3.2$ Hz)	1H	1, 3, 4, 10	H-1 α	H-1 α , H-1 β
		2.09 α	dd ($J = 12.8, 6.2$ Hz)	1H	1, 4, 6, 7, 10, 18, 19, 20	H ₂ -6	H-6 α , H-9 α , H ₃ -19 α
		1.76 α	overlap	1H	4, 5, 7, 8	H-5 α , H-6 β , H-7 α	H-5 α , H-6 β
3	213.5 s	1.56 β	overlap	1H	4, 5, 7, 8	H-5 α , H-6 α , H-7 α	H-5 α , H-6 α , H-7 β
		1.58 α	overlap	1H	5, 8, 9, 14	H ₂ -6, H-7 β	H-5 α , H-6 α
		1.17 β	overlap	1H	5, 8, 9, 14, 15	H-7 α	H-7 α
4	48.1 s						
5	49.2 d						
6	20.3 t	1.90 α	overlap	1H	1, 5, 7, 8, 10, 15, 20	H-11 α	H-5 α , H-11 α , H-12 α , H-19 α
		5.31 α	dd ($J = 5.3, 2.9$ Hz)	1H	8, 9, 10, 12, 13	H-9 α , H-12 α	H-9 α , H-12 α
		4.50 α	t ($J = 5.3$ Hz)	1H	13, 16	H-11 α	H-11 α , H-14 α
7	35.1 t						
8	35.0 s	1.77 α	overlap	1H	8, 9, 12, 13, 15, 16, 17, 2'	H-17 α , H-17 β	H-9 α , H-12 α , H-17 α
		1.14 β	s	3H	7, 8, 9, 14		H ₃ -16 β , H-17 β
		1.72 β	s	3H	12, 13, 14		H ₃ -15 β , H-17 β
9	56.4 d	2.83 α	dd ($J = 16.2, 4.9$ Hz)	1H	8, 13, 14, 1', 2'	H-14 α , H-17 β	H-7 α , H-14 α , H-17 β
		2.53 β	dd ($J = 16.2, 12.8$ Hz)	1H	13, 14, 1', 2', 3'	H-14 α , H-17 α	H ₃ -15 β , H ₃ -16 β , H-17 α
		1.61 β	s	3H	3, 4, 5, 19		H-6 β , H-7 β
10	47.7 s						
11	78.8d						
12	76.1 d						
13	88.7 s						
14	47.3 d						
15	16.6 q						
16	19.9q						
17	16.4 t	1.20 α	s	3H	3, 4, 5, 18		H-5 α , H-6 α
		21.4q					
		27.2 q					
18	21.4q						
19	27.2 q						
20	177.8 s						
1'	163.1 s						
2'	99.3 s						
3'	180.1 s						
4'	112.8 d	6.23	s	1H	2', 3', 5', 6'		H ₃ -6'
5'	161.4 s						
6'	19.3 q	2.07	s	3H	4', 5'		H-4'




Table S12. NMR data for **17** (^1H NMR:600 MHz, ^{13}C NMR: 150 MHz, δ in ppm, recorded in CDCl_3).

position	^{13}C		Multiplicity	intensity	HMBC correlation	COSY correlation	NOESY correlation
	δ (ppm)	δ (ppm)					
1	30.0 t	1.67 β	m	1H	2, 3, 5, 9, 10, 20	H-1 α , H-2 α	H-1 α , H $_3$ -15 β
		2.32 α	ddd ($J = 14.3, 11.6, 6.1$ Hz)	1H	2, 3, 5, 9, 10, 20	H-1 β , H $_2$ -2	H-6 α
2	30.1 t	2.45	m	2H	1, 3, 10, 11	H $_2$ -1	H-1 β
3	173.6 s						
4	145.7 s						
5	55.5 d	1.96 α	dd ($J = 13.0, 2.8$ Hz)	1H	1, 4, 6, 9, 10, 18, 19, 20	H-6 α , H-6 β	H-3 α , H-6 α , H-7 α , H-9 α , H $_3$ -19 α
6	23.6 t	1.88 β	overlap	1H	4, 5	H-5 α , H-6 α , H-7 α , H-7 β	H-1 α , H-6 β , H-7 β
		1.57 α	overlap	1H	4, 5, 8, 9	H-5 α , H-6 β , H-7 α , H-7 β	H-5 α , H-6 α
7	39.2 t	1.14 α	td ($J = 13.0, 3.5$ Hz)	1H	5, 6, 8, 9, 14, 15	H-6 α , H-6 β , H-7 β	H-6 α , H-7 β , H $_3$ -15 β , H-17 α
		1.92 β	m	1H	5, 6, 8, 9, 11, 15	H-6 α , H-6 β , H-7 α	H-6 α , H-7 α
8	37.8 s						
9	59.2 d	1.29 α	dd ($J = 12.3, 1.8$ Hz)	1H	10, 11, 12, 14, 15, 20	H-11 β	H-5 α , H-7 α , H-11 α , H-12 α , H-14 α
10	40.6 s						
11	21.3 t	1.64 β	overlap	1H	9, 12, 13, 14	H-9 α , H-11 α , H-12 α , H-12 β	H-11 α , H $_3$ -15 β
		1.86 α	m	1H	10, 13	H-11 β , H-12 β	H-1 α , H-9 α , H-11 β , H-12 α
12	40.4 t	2.20 α	m	1H	9, 11, 13, 14, 16	H-11 β , H-12 β	H-9 α , H-11 α , H-14 α
		1.74 β	dd ($J = 13.0, 3.7$ Hz)	1H	9, 11, 13, 14, 16	H-11 α , H-11 β , H-12 α	H-11 β , H $_3$ -16 β
13	83.6 s						
14	52.1 d	1.54 α	overlap	1H	8, 9, 13, 16, 17, 2'	H-17 α , H-17 β	H-9 α , H-12 α , H-17 α
15	15.3 q	0.91 β	s	3H	7, 8, 9, 14, 16, 20		H-1 α , H-1 β , H-7 β , H $_3$ -16 β , H-17 β
16	20.6 q	1.32 β	s	3H	10, 13, 14		H-11 β , H-12 β , H $_3$ -15 β , H-17 β
17	15.7 t	2.15 β	dd ($J = 16.3, 12.7$ Hz)	1H	8, 13, 14, 1', 2', 3'	H-14 α , H-17 α	H-7 β , H $_3$ -15 β , H $_3$ -16 β , H-17 α
		2.59 α	dd ($J = 16.3, 4.9$ Hz)	1H	8, 13, 14, 1', 2', 3'	H-14 α , H-17 β	H-14 α , H-17 β
18	21.0 q	1.78	s	3H	4, 5, 6, 10, 19		H-2 β , H-5 α
19	116.6 t	4.93 α	s	1H	4, 5, 18		H $_3$ -18 β
		4.74 β	s	1H	4, 5, 18		
20	67.9 t	4.44 α	d ($J = 12.4$ Hz)	1H	1, 3, 5, 9, 10		H $_3$ -15 β
		4.15 β	d ($J = 12.4$ Hz)	1H	1, 3, 5, 9, 10		H-11 β , H $_3$ -15 β
1'	162.6 s						
2'	98.5 s						
3'	180.7 s						
4'	112.2 d	6.00	s	1H	2', 3', 5', 6'		H $_3$ -6'
5'	160.9 s						
6'	19.5 q	2.21	s	3H	4', 5'		H-4'




Figure S1. UV spectra of metabolites isolated in this study.




Figure S2. SDS-PAGE analysis of the purified protein OlcF'.




Figure S3. ¹H NMR spectrum of chevalone F (9).




Figure S4. ¹³C NMR spectrum of chevalone F (9).




Figure S5. ¹H NMR spectrum of chevalone N (**10**).




Figure S6. ¹³C NMR spectrum of chevalone N (10).




Figure S7. HSQC spectrum of chevalone N (**10**).




Figure S8. HMBC spectrum of chevalone N (**10**).




Figure S9. ^1H - ^1H COSY spectrum of chevalone N (**10**).




Figure S10. ROESY spectrum of chevalone N (**10**).




Figure S11. ¹H NMR spectrum of chevalone O (**11**).




Figure S12. ¹³C NMR spectrum of chevalone O (11).




Figure S13. HSQC spectrum of chevalone O (**11**).




Figure S14. HMBC spectrum of chevalone O (**11**).




Figure S15. ^1H - ^1H COSY spectrum of chevalone O (**11**).




Figure S16. ROESY spectrum of chevalone O (**11**).




Figure S17. ¹H NMR spectrum of chevalone P (12).





Figure S18. ¹³C NMR spectrum of chevalone P (**12**).






Figure S20. HMBC spectrum of chevalone P (12).




Figure S21. ^1H - ^1H COSY spectrum of chevalone P (**12**).




Figure S22. ROESY spectrum of chevalone P (12).




Figure S23. ¹H NMR spectrum of chevalone Q (**13**).




Figure S24. ¹³C NMR spectrum of chevalone Q (13).




Figure S25. HSQC spectrum of chevalone Q (**13**).




Figure S26. HMBC spectrum of chevalone Q (**13**).




Figure S27. ^1H - ^1H COSY spectrum of chevalone Q (**13**).




Figure S28. ROESY spectrum of chevalone Q (**13**).




Figure S29. ¹H NMR spectrum of chevalone R (**14**).




Figure S30. ¹³C NMR spectrum of chevalone R (**14**).




Figure S31. HSQC spectrum of chevalone R (**14**).




Figure S32. HMBC spectrum of chevalone R (**14**).




Figure S33. ^1H - ^1H COSY spectrum of chevalone R (14).





Figure S34. ROESY spectrum of chevalone R (**14**).






Figure S36. ¹³C NMR spectrum of chevalone S (15).




Figure S37. ¹H NMR spectrum of chevalone T (16).




Figure S38. ¹³C NMR spectrum of chevalone T (**16**).




Figure S39. HSQC spectrum of chevalone T (**16**).




Figure S40. HMBC spectrum of chevalone T (**16**).




Figure S41. ^1H - ^1H COSY spectrum of chevalone T (**16**).




Figure S42. ROESY spectrum of chevalone T (**16**).




Figure S43. ¹H NMR spectrum of **17**.




Figure S44. ^{13}C NMR spectrum of **17**.




Figure S45. HSQC spectrum of **17**.




Figure S46. HMBC spectrum of **17**.




Figure S47. ^1H - ^1H COSY spectrum of **17**.




Figure S48. ROESY spectrum of **17**.

Supplementary References

1. J. Paluka, K. Kanokmedhakul, M. Soyong, K. Soyong and S. Kanokmedhakul, *Fitoterapia*, 2019, **137**, 104257.
2. A. Boto, R. Freire, R. Hernández, E. Suárez and M. S. Rodríguez, *J. Org. Chem.*, 1997, **62**, 2975-2981.